drugset
drugset / Trial / NCT05193292

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

NCT05193292 ↗

Phase 2 Unknown 77 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

This study aimed to evaluate the efficacy and safety of camrelizumab combined with trastuzumab and chemotherapy in Patients with HER2-positive advanced colorectal cancer

Timeline

Start
2022-01
Primary completion
2024-01
Completion
2025-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Trastuzumab Monoclonal antibody 6 mg/kg Intravenous
Background Capecitabine Small molecule 800 mg/m2 Oral
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Irinotecan Small molecule 180 mg/m2 Intravenous
Background Irinotecan Small molecule 200 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background S-1 Small molecule 40 mg/m2 Oral
Background S-1 Small molecule 60 mg/m2 Oral
Background fluorouracil Small molecule 400 mg/m2 Intravenous
Background fluorouracil Small molecule 1200 mg/m2 Intravenous

Indications

colorectal cancer